New Harvard-Developed AI Predicts Future Pancreatic Cancer Up to Three Years Before Diagnosis

The AI model can identify individuals with the highest risk of pancreatic cancer up to three years prior to their formal diagnosis. A new study, led by researchers from Harvard Medical School, the University of Copenhagen, VA Boston Healthcare System, Dana-Farber Cancer Institute, and the Harvard T

Related Keywords

Boston ,Massachusetts ,United States ,Dana Farber Cancer Institute ,Denmark ,Copenhagen ,Køavn ,Danish ,American ,Novo Nordisk ,Siamack Ayandeh ,Eli Lilly ,Chunlei Zheng ,Elizabeth Andrews ,Michaelh Rosenthal ,Alexandra Franz ,Gregory Antell ,Jessicax Hjaltelin ,Davide Placido ,Peter Kraft ,Aviv Regev ,Alexander Chowdhury ,Renato Umeton ,Maryt Brophy ,Chris Sander ,Nathanaelr Fillmore ,Brianm Wolpin ,Jihye Kim ,Chen Yuan ,Intomicsas Wolpin ,Lauren Brais ,Jura Bio ,Piotrj Chmura ,Bob Parsons Fund ,University Of Copenhagen ,Department Of Systems Biology ,Us Veterans Health Administration ,Protein Research ,Harvard Medical School ,Genentech ,Pancreatic Cancer Action Network ,Cancer Lustgarten Foundation ,Hale Family Center ,Pancreatic Cancer Research ,Wexler Family Fund ,National Institutes Of Health ,Syros Pharmaceuticals ,Va Cooperative Studies Program ,Blavatnik Institute ,Novo Nordisk Foundation Center ,Novo Nordisk Foundation ,Noble Effort Fund ,American Heart Association ,Illustration Targeting Cancer Cells ,Healthcare System ,Public Health ,Nature Medicine ,Systems Biology ,Health Administration ,Veteran Affairs ,Lustgarten Foundation ,National Institutes ,Studies Program ,Uniformed Services University ,Health Sciences ,Pancreatic Cancer ,Hoba Therapeutics Aps ,Celsius Therapeutics ,Thermo Fisher Scientific ,Neogene Therapeutics ,Dyno Therapeutics ,Tectonic Therapeutic ,